Observational studyPediatric nephrology (Berlin, Germany)2019
Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome.
Observational study in Pediatric nephrology (Berlin, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Pediatric idiopathic steroid-sensitive nephrotic syndrome: diagnosis and therapy -short version of the updated German best practice guideline (S2e) - AWMF register no. 166-001, 6/2020.Pediatric nephrology (Berlin, Germany) · 2021Guideline
- B-cell-targeting therapies in podocytopathies.Pediatric nephrology (Berlin, Germany) · 2026Review
- Comparison of efficacy of single-dose and double-dose rituximab in the treatment of refractory nephrotic syndrome in children: a retrospective study.Pediatric nephrology (Berlin, Germany) · 2026Article
- The safety of rituximab in pediatric nephrotic syndrome patients: a pharmacovigilance study of the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The efficacy of rituximab in pediatric patients with steroid-dependent or frequent relapsing nephrotic syndrome due to MCD or FSGS.Frontiers in medicine · 2026Article
- Management of rituximab in patients with PLA2R-associated membranous nephropathy of different age: a single-center retrospective cohort study.Renal failure · 2025Article
- Clinical practice guidelines for rituximab treatment in children with steroid-sensitive nephrotic syndrome.World journal of pediatrics : WJP · 2025Review
- Single (375 mg/mPediatric nephrology (Berlin, Germany) · 2025Article
- Long Term Evaluations of First Single-dose Rituximab in Children with Steroid-Dependent Minimal-Change Nephrotic Syndrome.Renal failure · 2024Observational
- Using real-world data to inform dosing strategies of rituximab for pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome: a prospective pharmacokinetic-pharmacodynamic study.Frontiers in pharmacology · 2023Article
- The outcome of rituximab in treating steroid dependent nephrotic syndrome.: Histopathology and immunosuppressive drugs as predicting factors.Saudi medical journal · 2022Article
- Efficacy of rituximab therapy in children with nephrotic syndrome: a 10-year experience from an Iranian pediatric hospital.BMC pediatrics · 2022Article
- Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?Journal of clinical medicine · 2021Review
- Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective studyTurkish journal of medical sciences · 2021Article
- Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen.Pediatric nephrology (Berlin, Germany) · 2021Review
- Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study.Therapeutic advances in neurological disorders · 2021Article
- Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome.Frontiers in pharmacology · 2021Article
- Clinical Response and Pattern of B cell Suppression with Single Low Dose Rituximab in Nephrology.Kidney360 · 2020Article
- Rituximab Use in the Management of Childhood Nephrotic Syndrome.Frontiers in pediatrics · 2019Review
- Rituximab therapy for childhood onset idiopathic nephrotic syndrome: experience of a Portuguese tertiary center.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRituximab is an effective treatment for children with steroid dependent or frequently relapsing nephrotic syndrome. The optimum dosing schedule for rituximab has not been established. We hypothesized that a single low dose of 375 mg/m
methodsWe conducted a multicenter retrospective observational cohort study of children with steroid-sensitive frequently relapsing nephrotic syndrome. Data were extracted from clinical records including the dates of diagnosis, treatment, relapses, the use of concomitant immunosuppression, and lymphocyte subset profiling. Patients treated earlier received variable doses of rituximab, although typically two doses of 750 mg/m
resultsSixty patients received 143 courses of rituximab. Seven different dosing regimen strategies were used, ranging between 375 and 750 mg/m
conclusionsUse of a single low-dose regimen of rituximab in the management of frequently relapsing nephrotic syndrome does not affect the probability of relapse at 12 months or time to B cell reconstitution compared to a conventional higher dose.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.